CN110384707A - Antineoplastic pharmaceutical compositions and its application - Google Patents
Antineoplastic pharmaceutical compositions and its application Download PDFInfo
- Publication number
- CN110384707A CN110384707A CN201910808593.7A CN201910808593A CN110384707A CN 110384707 A CN110384707 A CN 110384707A CN 201910808593 A CN201910808593 A CN 201910808593A CN 110384707 A CN110384707 A CN 110384707A
- Authority
- CN
- China
- Prior art keywords
- triptolide
- chrysin
- pharmaceutical composition
- cell
- chr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to biomedicine technical field, it is related to a kind of antineoplastic pharmaceutical compositions and its application.Wherein, which includes: triptolide and Chrysin.Antineoplastic pharmaceutical compositions provided by the invention are by triptolide and Chrysin use in conjunction, the dosage of two kinds of drugs can be reduced, to reduce the toxic side effect of triptolide, and relative to exclusive use triptolide or Chrysin, moreover it is possible to significantly increase the inhibition and/or therapeutic effect to liver cancer.Moreover, since triptolide is expensive, Chrysin price is less expensive, and the two is combined the cost that can reduce pharmaceutical composition.
Description
Technical field
The invention belongs to biomedicine technical fields, more particularly, to a kind of antineoplastic pharmaceutical compositions and its application.
Background technique
Liver cancer is one of current universally acknowledged higher tumour of the death rate, and in China, the death rate occupies the 3rd of malignant tumour,
China dies of liver cancer there are about 38.3 ten thousand people every year, and the 51% of Zhan Quanqiu PLC mortality sum.Liver cancer have onset concealment, be in progress it is fast
Speed, easily transfer, the features such as patient survival is short, majority be in middle and advanced stage when being found, therefore clinical liver cancer treatment is mainly change
Treat drug therapy and targeted drug treatment.
Triptolide (triptolide, TP) is also known as triptolide, is extracted from Celastraceae plant tripterygium wilfordii
A kind of Diterpenoid epoxide lactone compound, be the principle active component of the preparations such as leigongteng tablets, Glucosidorum Tripterygll Totorum, clinic is multi-purpose
In anti-inflammatory and immunosupress.Recent studies suggest that it can be in nasopharyngeal carcinoma, breast cancer, liver cancer, gastric cancer, lung cancer, cancer of pancreas, colon
Antitumor action is played in the Several Kinds of Malignancy such as cancer, cervical carcinoma, oophoroma and its tumor cell line, the anticancer with wide spectrum is living
Property.The antitumor mechanism of triptolide is very extensive.TP can inhibit cell to increase by Fas apoptotic pathway, from mitochondria pathway
It grows and induces cell apoptosis, it includes that the generation of active oxygen (ROS) and er stress are situated between that the signal of upstream can also be activated by ERK
The PERK-eIF2 α access led plays apoptosis-induced effect, can also be by inducing tumour cell autophagy, arresting cell cycle, inhibition
The approach such as Tumor Angiongesis, reverse multiple drug resistance of tumor play antitumor action.However the therapeutic window of triptolide is narrow, it is long
Phase greatly limits the application of triptolide using caused drug accumulation toxicity.Chrysin (chrysin, C HR) is from purple
The one kind extracted in prestige section plant oroxylum indicum has the flavone compound of extensive pharmacological action.The molecular formula of Chrysin is
C15H10O4, molecular weight 254.24 is dissolved in alkali hydroxide solution, is dissolved in acetone at room temperature, is slightly soluble in ether, ethyl alcohol and chlorine
It is imitative, it is not soluble in water, it is water-soluble and fat-soluble all poor.Chrysin have anti-oxidant, antiviral, anti-hypertension, it is hypoglycemic and
The effects of inhibiting aromatase activity, especially it, which has, prevents and treats function of tumor, and has adverse reaction small low with toxicity
The advantages that.Research shows that Chrysin can be by making PI3K/Akt signal pathway inactivation, lowering N F- κ B expression and activation IAP
(inhibitor of apoptosis proteins) inducing apoptosis of tumour cell.Due to Chrysin water solubility and it is fat-soluble
It is poor, significantly limit its application clinically.In order to improve the water solubility and enhancing metabolic stability of Chrysin, people
A large amount of modification retrofit work has been carried out to its structure, obtained numerous chrysin derivatives with potential pharmacological activity.
To sum up, since existing chemotherapeutics effect is poor, toxic side effect is big, drug resistance is high, newly efficient is found
The drug of the treatment liver cancer of low toxicity is of great significance.
Summary of the invention
The object of the present invention is to provide antineoplastic pharmaceutical compositions associated with a kind of triptolide and Chrysin and its answer
With to reduce the toxic side effect of triptolide, and inhibition and/or therapeutic effect of the increase to tumour.
To achieve the goals above, first aspect present invention provides a kind of antineoplastic pharmaceutical compositions.The pharmaceutical composition
It include: triptolide and Chrysin.
In the present invention, described pharmaceutical composition includes the solution of triptolide and Chrysin；Triptolide is in institute
Stating the concentration in solution is 1.56nM~6.25nM；Concentration of the Chrysin in the solution is 2.5 μM~10 μM.
In view of therapeutic effect and cytotoxicity, it is preferable that concentration of the triptolide in described pharmaceutical composition is
3.125nM~6.25nM；Concentration of the Chrysin in described pharmaceutical composition is 5 μM~10 μM.
Triptolide and Chrysin are dissolved in organic solvent respectively, such as dimethyl sulfoxide (DMSO), are made described
Triptolide mother liquor and the Chrysin mother liquor.Public rattan A prime mother liquor and the Chrysin mother liquor are answered in proportion in application
Match, described pharmaceutical composition is made.
It will be appreciated by persons skilled in the art that the pharmaceutical composition using triptolide and Chrysin as host agent, is gone back
It may include pharmaceutically acceptable auxiliary material.Auxiliary material include: water for injection, solubilizer, cosolvent, antioxidant, pH adjusting agent,
At least one of isotonic regulator, emulsifier, adsorbent, complexing agent etc..
The present invention is not defined the administration mode of the pharmaceutical composition, can be administered using different dosage forms, in order to
Facilitate administration and drug absorption, the dosage form of described pharmaceutical composition is injection.
Second aspect of the present invention also provides aforementioned pharmaceutical compositions and inhibits and/or treat the preparation of HepG2 cell in preparation
In application.
Third aspect present invention also provides aforementioned pharmaceutical compositions and inhibits in preparation and/or treat in the preparation of tumor disease
Application.Tumor disease includes: liver cancer, gastric cancer, lung cancer, colon cancer, breast cancer, oophoroma, cervical carcinoma, prostate cancer, bone and flesh
Tumor and myeloma etc..
Specifically, the tumor disease is liver cancer.
Triptolide is a kind of Diterpenoid epoxide lactone compound, and still toxic side effect is big extensively for antitumor mechanism.White poplar
Element is the days that a kind of flavone compound, small toxicity, and chromocor compound are the relevant tyrosine protein kinase of bcr-abl albumen
Right inhibitor, Chrysin can pass through PI3K/Akt signal pathway inducing apoptosis of tumour cell.Anti-tumor drug provided by the invention
Triptolide and Chrysin use in conjunction can be reduced the dosage of two kinds of drugs by composition, to reduce triptolide
Toxic side effect, and relative to exclusive use triptolide or Chrysin, moreover it is possible to it significantly increases the inhibition to liver cancer and/or controls
Therapeutic effect.Moreover, since triptolide is expensive, Chrysin price is less expensive, and the two combination can also reduce anti-swollen
The cost of tumor medicine composition.
Since triptolide has a variety of antitumor mechanism, there is good inhibiting effect to kinds of tumors, therefore,
Pharmaceutical composition provided by the invention can be applied to preparation and inhibit and/or treat in the preparation of tumor disease, especially prepare
In the preparation of inhibition and/or treatment liver cancer.
Other features and advantages of the present invention will then part of the detailed description can be specified.
Detailed description of the invention
Exemplary embodiment of the invention is described in more detail in conjunction with the accompanying drawings, it is of the invention above-mentioned and its
Its purpose, feature and advantage will be apparent.
Fig. 1 shows the HepG2 cell scratch Healing Experiments result figure in test case 2.
Fig. 2 shows being dyed using Hochest33258 to HepG2 cell in test case 3 in 48h, observe
The apoptosis result figure of HepG2 cell.
Fig. 3 shows the apoptosis rate knot of the HepG2 cell handled in test case 4 by Flow cytometry different dosing
Fruit figure.
Specific embodiment
The preferred embodiment of the present invention is described in more detail below.Although the following describe preferred implementations of the invention
Mode, however, it is to be appreciated that may be realized in various forms the present invention without that should be limited by the embodiments set forth herein.
Drug used in following embodiments and reagent are as follows:
Triptolide bulk pharmaceutical chemicals, Wuhan Ding Hui Chemical Co., Ltd., purity > 98%；Chrysin, Shanghai source leaf biology
Co., Ltd, lot number: X24O6C4947, purity > 98%；DMEM high sugar cell culture medium, Gibco company, the U.S., lot number:
8118326；Penicillin, streptomysin, Hyclone company, the U.S., lot number: 1677648；Fetal calf serum, Gibco company, the U.S., batch
Number: 42F0266K；0.25% trypsase (contains 0.02%EDTA), Gibco company, the U.S., lot number: 2042337；PBS, the U.S.
Gibco company, lot number: AC11496277；MTT, German Biofroxx company, lot number: EZ3455C328；Hoechst33258 dye
Toner, sigma company, the U.S., lot number: B2883；AnnexinV-FITC/PI apoptosis detection kit, Shanghai assist sage's biotechnology
Co., Ltd, lot number: A9807170.
Instrument used in following embodiments is as follows:
CKX41-A32PH type inverted microscope, Japanese Olympus company；W200IR type carbon dioxide incubator, Jin Xi
Alliance (Beijing) Instrument Ltd.；The three-dimensional pressure steam sterilization boiler of YM30Z, Shanghai Sanshen Medical Instrument Co., Ltd.；AL204
Type electronic balance, Mettler Toledo Inc.；T GL-16C- type centrifuge, Anting Scientific Instrument Factory, Shanghai；KQ3200E type is super
Sound wave washer, Kunshan Ultrasonic Instruments Co., Ltd.；Sunrise microplate reader, Tecan company, Switzerland；SW-CJ-1FD type is ultra-clean
Workbench, the safe and sound air technique Co., Ltd of Su Jing；PHG-9070A type electric heating constant-temperature blowing drying box, the upper macro experiment of Nereid are set
Standby Co., Ltd；Cytoflex flow cytometer, Beckman Coulter Inc.；HH-S1 type digital display thermostat water bath, Jintan
Medical Instruments factory, city.
Mode cell used in following embodiments is as follows:
Hepatoma Hep G 2 cells are purchased from hundred Ao Si Biotechnology Co., Ltd of Hubei.
Liver L02 cell is given by Central China University of Science and Technology's School of Public Health midsummer teacher laboratory.
Preparation example 1
Triptolide mother liquor (hereinafter referred to as TP): it weighs appropriate triptolide powder and is dissolved in suitable dimethyl Asia
In sulfone (DMSO), 0.22 μm of membrane filtration obtains the TP mother liquor of 1mmol/L, spare.
Chrysin mother liquor (hereinafter referred to as CHR): weighing appropriate Chrysin powder and be dissolved in suitable DMSO, 0.22 μm of filter
Film filtering, obtains the CHR mother liquor of 20mmol/L, spare.
Test case 1
This test case is using mtt assay detection TP and CHR drug combination (pharmaceutical composition of the invention) to HepG2 and L02
The influence of cell Proliferation.
Logarithmic growth phase hepatoma Hep G 2 cells and liver L02 cell are disappeared with 0.25% trypsase (containing 0.02%EDTA)
After change, adjust to suitable cell number concentration, blood counting chamber counts, cell is diluted to after debita spissitudo and is inoculated in 96 orifice plates
In, 100 μ L culture mediums are added in every hole, and cell concentration is 4 × 104A/mL.After culture for 24 hours, old culture solution is discarded, every hole adds
Enter the fresh complete medium of 100 μ L, then is separately added into the administration group medical fluid of the various concentration of serum free medium preparation.Experiment
Be divided into the mono- medicine group of TP, the mono- medicine group of CHR, TP+CHR combination group, every group of TP final concentration be respectively 1.56nmol/L, 3.125nmol/L,
6.25nmol/L, CHR final concentration are respectively 2.5 μm of ol/L, 5 μm of ol/L, 10 μm of ol/L.100 μ L are separately added not in blank control wells
Dosing serum free medium, 3 multiple holes of every group of setting.Be put into incubator continue respectively culture for 24 hours, after 48h, 72h, every hole adds
Enter 20 μ L MTT solution (final concentration of 0.5mg/mL), continues to be put into carbon dioxide incubator and cultivate 4h, it is careful to be sucked out in hole
Culture medium, every hole is added the dimethyl sulfoxide (DMSO) of 150 μ L, is placed in setting concussion in microplate reader and rocks 10min, make in hole
Purple crystal be completely dissolved, absorbance value (OD value) is measured under 490nm wavelength.Calculate inhibiting rate, inhibiting rate (%)=(1-
Experimental group OD value/control group OD value) × 100%.
Various concentration administration group upon administration for 24 hours, 48h, 72h Tables 1 and 2 is shown in the inhibiting rate of HepG2 and L02 cell.
Influence (n=3) of table 1TP and the CHR drug combination to HepG2 cell Proliferation
Influence (n=3) of table 2TP and the CHR drug combination to L02 cell Proliferation
As can be seen from Table 1 and Table 2, the mono- medicine group of TP, the mono- medicine group of CHR and drug combination (pharmaceutical composition) group are equal
There is time-effect relationship to the inhibiting rate of HepG2, and combination group is higher than single medicine group to the inhibiting rate of cell, TP and CHR show good
Good synergistic effect.And while the two combination is lower than the mono- medicine group of TP to the toxic effect of normal liver cell L02, illustrate CHR and TP
Combination can reduce the toxic effect and synergy of TP, have the function that Synergy and attenuation.
Test case 2
This test case detects influence of the different dosing processing to HepG2 cell migration ability.
The HepG2 cell suspension of logarithmic growth phase, adjustment cell concentration are 5 × 105A/mL is inoculated in 6 orifice plates, often
Hole is inoculated with 2mL, is put in carbon dioxide cell incubator and is incubated for for 24 hours, with 200 μ L after bottom hole covers with one layer of cell monolayer for 37 DEG C
Pipette tips draw a straight line, and remove old culture medium, and the cell crossed out is cleaned with PBS.The fresh complete medium of 1mL is added in every hole,
It is separately added into the administration group medical fluid of the various concentration of serum free medium preparation again.It tests and is divided into the mono- medicine group of TP, the mono- medicine group of CHR,
TP+CHR drug combination group, TP final concentration are respectively 6.25nmol/L, and CHR final concentration is respectively 10 μm of ol/L, separately set serum training
The control wells of nutrient solution and cell, every hole 2mL, 37 DEG C, 5%CO after administration2Continue to be incubated in incubator.Administration 0h, for 24 hours,
48h observes cell scratch healing state using inverted microscope and takes pictures.Referring to Figure 1, Fig. 1 is shown in test case 2
HepG2 cell scratch Healing Experiments result figure.As shown in Figure 1, blank group is over time, healing rate increases；(TP is mono- for medication group
The mono- medicine group of medicine group, CHR and TP+CHR drug combination) there is different degrees of healing suppression.Wherein CHR group heals
Phenomenon is obvious, and there was no significant difference compared with the control group for healing rate, to cell migration almost without inhibiting effect, the mono- medicine group of TP
It is remarkably decreased with CHR+TP drug combination group healing rate, shows to illustrate TP to the stronger inhibition migration of HepG2 cell
The inhibition of metastasis effect to HepG2 cell can be enhanced with CHR combination (pharmaceutical composition of the invention).
Test case 3
The HepG2 Apoptosis situation that this test case passes through the dyeing observation different dosing processing of Hoechst 33258.
The HepG2 cell suspension of logarithmic growth phase, adjustment cell concentration are 5 × 104A/ml is inoculated in 6 orifice plates, often
Hole 2mL is put in carbon dioxide cell incubator and is incubated for for 24 hours for 37 DEG C, and old culture solution is discarded after cell is adherent, and every hole is added
1mL fresh complete medium, then it is separately added into the administration group medical fluid of the various concentration of serum free medium preparation.Experiment is divided into
The mono- medicine group of TP, the mono- medicine group of CHR, TP+CHR combination group, TP final concentration are respectively 6.25nmol/L, and CHR final concentration is respectively 10 μ
Mol/L, separately sets the control wells of serum free culture system liquid and cell, and every hole 2ml continues to be incubated for 37 DEG C after administration, in 5%CO2 incubator.
Old culture medium is sucked after effect 48h, every hole is washed twice with PBS, is separately added into the fixed 30min of 4% paraformaldehyde of 2mL, is sucked
Fixer, then washed twice with PBS, the Hoechst dye liquor (10 μ g/mL) of 1mL is added in every hole, goes to dye after being protected from light dyeing 15min
Liquid, every hole are washed twice with PBS, are taken pictures immediately in observation on fluorescence microscope.Referring to fig. 2, Fig. 2 shows in test case 3
HepG2 cell is dyed using Hochest33258 when 48h, the HepG2 cell observed.It is empty as shown in Fig. 2 (A)
White cellular control unit is completely full, and nucleus is dyed to light blue.As shown in Fig. 2 (B), 2 (C) and 2 (D), single medicine group and joint
The HepG2 cell quantity of medication group substantially reduces, it is seen that typical apoptosis morphology variation, nucleus is shinny, and
There is phenomena such as collection pyknosis of core side, fragmentation, chromatic agglutination, apoptotic body.As shown in Fig. 2 (D), CHR+TP group apoptosis phenomenon
It is become apparent from than single medicine group, nucleus side collection pyconsis is more significant, and cell survival quantity is less.Therefore, drug combination group pair
The inhibitory effect of HepG2 cell is more significant.
Test case 4
The apoptosis situation for the HepG2 cell that this test case is handled by Flow cytometry different dosing.
Fig. 3 is referred to, Fig. 3 shows the HepG2 cell handled in test case 4 by Flow cytometry different dosing
Apoptosis rate result figure.As shown in figure 3, compared with blank not administration group (referring to Fig. 3 A), after drug treatment 48 hours, TP
The apoptosis rate (referring to Fig. 3 C) of single medicine group does not have significant difference, and the mono- medicine group of CHR (referring to Fig. 3 B) and CHR+TP joint are used
Medicine group (referring to Fig. 3 D) dramatically increases the apoptosis rate of cell, and wherein drug combination group apoptosis rate is higher than single medicine group, illustrates CHR
Synergistic anti-liver cancer and anti-HepG2 cell is combined with TP.
Apoptosis rate of the HepG2 cell of 3 different dosing of table processing at 48h hours
Table 3 is referred to, relative to blank control group, after the mono- medicine group of TP, the mono- medicine group of CHR and the processing of CHR+TP drug combination group
HepG2 apoptosis rate increase, and the HepG2 apoptosis rate of the mono- medicine group of CHR is significantly higher than the mono- medicine group of TP, CHR+TP connection
The HepG2 apoptosis rate for sharing medicine group is significantly higher than the mono- medicine group of CHR.Thus can also illustrate, CHR and TP combination are synergistic anti-
Hepatoma Hep G 2 cells.
By above-mentioned test case it is found that the concentration of the triptolide in antineoplastic pharmaceutical compositions provided by the invention is
1.56nM~6.25nM, 50 μM of concentration well below triptolide disclosed in present document act on hepatoma Hep G 2 cells,
And 5~25 μM act on liver cancer MHCC-97H cell.And the concentration of Chrysin is 2.5 μM~10 μM, also below existing
The concentration of Chrysin disclosed in document.At such low concentrations, triptolide and Chrysin combination display to the proliferation of HepG2,
Migration has significant inhibiting effect, has concentration and time dependence, and induce HepG2 Apoptosis, to normal liver cell L02
The toxicity very little of cell.
Various embodiments of the present invention are described above, above description is exemplary, and non-exclusive, and
It is not limited to disclosed each embodiment.Without departing from the scope and spirit of illustrated each embodiment, for this skill
Many modifications and changes are obvious for the those of ordinary skill in art field.
Claims (9)
1. a kind of antineoplastic pharmaceutical compositions, which is characterized in that described pharmaceutical composition includes: triptolide and Chrysin.
2. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition include triptolide and
The solution of Chrysin；Concentration of the triptolide in the solution is 1.56nM~6.25nM；Chrysin is in the solution
Concentration be 2.5 μM~10 μM.
3. pharmaceutical composition according to claim 2, which is characterized in that triptolide is in described pharmaceutical composition
Concentration is 3.125nM~6.25nM；Concentration of the Chrysin in described pharmaceutical composition is 5 μM~10 μM.
4. pharmaceutical composition according to claim 2, which is characterized in that the solvent of the solution is dimethyl sulfoxide.
5. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition further includes that can pharmaceutically connect
The auxiliary material received.
6. pharmaceutical composition according to claim 1-5, which is characterized in that the dosage form of described pharmaceutical composition is
Injection.
7. pharmaceutical composition described in any one of claims 1-6 inhibits in preparation and/or treats in the preparation of HepG2 cell
Using.
8. pharmaceutical composition described in any one of claims 1-6 inhibits in preparation and/or treats in the preparation of tumor disease
Using.
9. application according to claim 8, which is characterized in that the tumor disease is liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910808593.7A CN110384707A (en) | 2019-08-29 | 2019-08-29 | Antineoplastic pharmaceutical compositions and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910808593.7A CN110384707A (en) | 2019-08-29 | 2019-08-29 | Antineoplastic pharmaceutical compositions and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110384707A true CN110384707A (en) | 2019-10-29 |
Family
ID=68289542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910808593.7A Pending CN110384707A (en) | 2019-08-29 | 2019-08-29 | Antineoplastic pharmaceutical compositions and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110384707A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190134152A1 (en) * | 2017-11-06 | 2019-05-09 | Stalicla S.A. | Treatment of a subtype of asd |
-
2019
- 2019-08-29 CN CN201910808593.7A patent/CN110384707A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190134152A1 (en) * | 2017-11-06 | 2019-05-09 | Stalicla S.A. | Treatment of a subtype of asd |
Non-Patent Citations (2)
| Title |
|---|
| 孙祥明等: "白杨素抑制肝癌细胞生长和诱导细胞凋亡", 《中国科技论文在线》 * |
| 尹亮等: "雷公藤甲素对人肝癌细胞株HepG2体内外作用的研究", 《南京医科大学学报（自然科学版）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105111271B (en) | A kind of ursolic acid-Aspirin Conjugate and the application in preparation prevention tumor metastasis medicine thereof | |
| Zhao et al. | A flavonoid component from Docynia delavayi (Franch.) Schneid represses transplanted H22 hepatoma growth and exhibits low toxic effect on tumor-bearing mice | |
| Jin et al. | Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways | |
| CN109320570A (en) | A kind of icariside I class compound, derivative, officinal salt and application | |
| CN104906558B (en) | The pharmaceutical composition containing ulinastatin for the treatment of cervical cancer | |
| CN105287627A (en) | Unsaturated lactone ingredient and chemotherapy drug composition and application thereof | |
| CN102614170A (en) | Application of artemisinin B in preparation of antitumor drugs | |
| CN105920019B (en) | A kind of pharmaceutical composition and its application in preparation of anti-tumor drugs containing ursolic acid and Sorafenib | |
| CN102030813B (en) | Preparation method and application of yellow ginger zingiberensis saponin having high-efficiency anti-cancer activity | |
| CN103142774B (en) | Application of total saponin extract of lobedfruit schizocapsarhizome in treatment of liver cancer and nasopharyngeal carcinoma | |
| CN110478346A (en) | Antineoplastic pharmaceutical compositions and its application | |
| CN110384707A (en) | Antineoplastic pharmaceutical compositions and its application | |
| CN103417554B (en) | A kind of antitumor medicine composition and its application | |
| CN108295085A (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN104628692A (en) | Limonin compound as well as pharmaceutical composition, preparation method and usage thereof | |
| CN105878270A (en) | Application of deuterium-depleted water as tumor multidrug-resistance reversal agent | |
| CN108864316A (en) | A kind of application in sulfonated tree peony seed polysaccharide and its preparation treatment liver cancer ancillary drug | |
| CN104055786B (en) | The application in preparation preventing and treating tumour medicine of medicagenic acid-3-O-β-D-pyranglucoside, medicagenic acid and salt thereof | |
| CN105732736B (en) | A kind of preparation method of phenylpropanoids | |
| CN106177035B (en) | Preparation method and application of effective rosa chinensis flower extract with blood sugar reducing and anticancer functions | |
| CN105708845B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN105884841B (en) | A kind of preparation method of phenylpropanoids | |
| CN107519216A (en) | Blood-snow tea antitumor active site and preparation method and application | |
| CN105030770B (en) | Application of the berberine in the medicine for preparing treatment acute myeloid leukemia | |
| CN109867657B (en) | Dihydroxydibenzo [ b, f ] [1,5] dioxacin ring compound, preparation method, pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191029 |